Discontinuing the CCB and switching to an alternative antihypertensive therapy will resolve the edema. Peripheral edema is an uncommon problem in patients with untreated hypertension because local ...

There have been inconsistent findings when switching from one dihydropyridine CCB to another or when switching to different formulations of the same drug to lessen or resolve peripheral edema.

ALBAWABA Your feet can reveal a lot about your overall health, including potential problems with your heart. Since the heart ...

The FDA has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone for transplant-ineligible, newly diagnosed multiple myeloma.

To ascertain the influence of colloid osmotic (oncotic) and hydrostatic pressure on excess lymph and edema formation in congestive heart failure, a disorder characterized by generalized venous ...

Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...

A new generation of catheters with a longer balloon, longer working length, and more pulses to manage calcified peripheral ...

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...

US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...

BOSTON & MONTREAL, September 26, 2024--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), is a clinical-stage ...

While chest pain is a common symptom of CVD, heart issues are often silent and can manifest over years through subtle signs that are easy to overlook Swelling in the ankles, also known as edema, can ...